Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G guidance

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble has upgraded its sales and EPS guidance for the second quarter of fiscal year 2006 due to strong sales and lower-than-expected costs for the Gillette acquisition, the firm states in a release Dec. 13. The company projects 25%-26% sales growth for the quarter, in the upper range of its previous estimates. EPS guidance has also moved to the upper margin of previous estimates to $0.68-$0.69, the Cincinnati-based firm reports. P&G estimates that its recently acquired Gillette business will dilute second-quarter earnings by $.08-$.10 per share rather than the previously forecasted $.09-.$12 per share. Additionally, Gillette turned out a strong performance in the second quarter with sales increasing 17% versus the previously estimated "flat to low-single digit sales growth," P&G states. The firm's $57 bil. purchase of Gillette closed in October...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel